Hair Loss Biopharma Firm Veradermics Raises $256 Million in IPO

The Connecticut-based company's shares priced above the marketed range in its upsized public offering.

Published on Feb. 3, 2026

Got story updates? Submit your updates here. ›

Veradermics Inc., a biopharmaceutical firm focused on hair restoration, raised $256.3 million in an upsized U.S. initial public offering. The company sold about 15 million shares at $17 each, above the previously marketed range of $14 to $16 per share. At the IPO price, Veradermics has a market value of around $596 million.

Why it matters

The successful IPO for Veradermics highlights investor interest in the hair loss treatment market, which is expected to grow significantly in the coming years as new therapies become available. The company's ability to raise more capital than initially planned suggests strong demand for its stock.

The details

Veradermics, which is backed by venture capital firm Longitude Capital, is a biopharmaceutical company focused on developing new treatments for hair loss and restoration. The company sold about 15 million shares in its IPO, up from the previously marketed 13.35 million shares, indicating high investor demand.

  • Veradermics held its IPO on February 4, 2026.

The players

Veradermics Inc.

A biopharmaceutical firm focused on hair restoration and new treatments for hair loss.

Longitude Capital

The venture capital firm that backs Veradermics.

Got photos? Submit your photos here. ›

What’s next

Veradermics plans to use the IPO proceeds to fund further research and development of its hair loss treatment pipeline, as well as for general corporate purposes.

The takeaway

Veradermics' successful IPO demonstrates the growing investor interest in the hair loss treatment market, as new therapies emerge to address this common medical condition.